C. Carbone, “TGF-β-Activated Kinase 1 (TAK1) Is an In Vivo Druggable Target for Reverting Pancreatic Cancer Chemoresistance”, JOP. J Pancreas (Online), vol. 14, no. 5S, p. 562, Sep. 2013.